fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Advertisment

VBL presents positive interim data from the OVAL phase III pivotal study of VB 111 in ovarian cancer at the ASCO meeting, showing 58% or higher objective response rate

Written by | 2 Jun 2020 | Pharmacy

VBL Therapeutics announced the presentation of the positive outcome of pre-planned interim analysis results from the OVAL Phase III pivotal clinical trial of VB III in platinum-resistant ovarian cancer at the American Society of Clinical Oncology (ASCO) 2020 virtual annual meeting. The analysis compared the CA-125 objective response rate (ORR) according to GCIG criteria in the treatment and control arms among the first 60 evaluable patients.

The CA-125 ORR in those patients was 53%. Assuming a balanced randomization, the response rate in the treatment arm (VB 111 in addition to weekly paclitaxel) was 58% or higher. In patients who had post-dosing fever, which is a marker for VB 111 treatment, the response rate was 69%. The CA-125 response rate observed in the Phase III interim analysis is at least as good as the response rate seen in the prior Phase II study, which enrolled a similar patient population and showed overall survival benefit.

In the previously reported Phase II study of VB 111 in platinum resistant ovarian cancer, 58% of the patients treated with VB 111 and paclitaxel demonstrated a CA-125 response. Those patients with a CA-125 response demonstrated a median overall survival of 808 days, versus 351 days for those patients without a CA-125 response.“The OVAL interim data are very encouraging as they demonstrate the potential benefit of VB 111 over standard-of-care in a randomized-controlled setting,” said Tami Rachmilewitz, M.D., Vice President Clinical Development of VBL Therapeutics. “With over 25% of the patients already enrolled in the study, we look forward to further advancing the OVAL study by expansion to Europe and Japan later this year.”

About the OVAL (VB 111-701/GOG-3018) study (NCT03398655) : OVAL is an international Phase III randomized, double-blind, placebo-controlled potential registration clinical trial that compares a combination of VB 111 and paclitaxel to placebo plus paclitaxel, in patients with platinum-resistant ovarian cancer. The study is planned to enroll approximately 400 patients. OVAL is conducted in collaboration with the GOG Foundation, Inc., an independent international non-profit organization with the purpose of promoting excellence in the quality and integrity of clinical and basic scientific research in the field of gynecologic malignancies.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.